Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Antengene & MSD Enter into a Global Clinical Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Antengene & MSD Enter into a Global Clinical Collaboration

The companies will evaluate the combination of ATG-022 and MSD's anti-PD-1 therapy, KEYTRUDA, in patients with advanced solid tumors.

By: Rachel Klemovitch

Assistant Editor

Antengene Corporation Limited (Antengene) has entered a global clinical collaboration with MSD (Merck & Co., Inc.) to evaluate the combination of ATG-022 and MSD’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with advanced solid tumors.

ATG-022 is a CLDN18.2-targeting antibody-drug conjugate (ADC). Data support meaningful efficacy across all levels of Claudin 18.2 expression in gastric cancer, including high, low, and ultra-low expressors.

Antengene presented the latest data from its Phase I/II CLINCH study at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Results showed an objective response rate (ORR) of 42.9% and a disease control rate (DCR) of 95.2% in patients with moderate to high CLDN18.2 expression (IHC 2+ ≥ 20%). 

Additionally, the study demonstrated an ORR of 30.0% and a DCR of 50.0% in patients with low CLDN18.2 expression (IHC 2+ < 20%).

ATG-022 also exhibited a favorable safety profile and extended treatment durations, with no observed cases of ophthalmological or neurological toxicities, nor interstitial lung disease.

The U.S. FDA has awarded Orphan Drug Designations to ATG-022, for gastric and pancreatic cancers.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters